Innovative Treatment Protocols That Can Redefine the Management of nAMD and DR

Author(s)/Faculty: Judy E. Kim, MD; Sophie J. Bakri, MD
Release Date: 10/19/2021Expiration Date: 10/18/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: VideoProvider:
Treatment protocols utilizing intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies in retinal diseases continue to evolve. In the management of neovascular age-related macular degeneration (nAMD), extending the treatment interval has the potential to maintain the significant visual acuity gains seen in pinnacle clinical studies, while reducing treatment burden. The emerging role of persistent retinal fluid on visual outcomes must also be taken into consideration, as these management protocols are being further refined. For patients with diabetic retinopathy (DR), early intervention with anti-VEGF therapies has been seen to reduce vision-threatening complications as well as slow disease progression, yet many patients with DR are not being offered this therapeutic option. In this CME activity, experts in the field evaluate clinical trials that assess the effectiveness of different anti-VEGF treatment protocols in the management of DR and nAMD, as well as examine the role of persistent subretinal and intraretinal fluid in determining response to treatment in patients with nAMD.